AHCL
Anlon Healthcare Limited (AHCL) Stock Analysis
Anlon Healthcare Limited is an Indian pharmaceutical company manufacturing formulations and healthcare products. It supplies medicines to domestic markets through distributors and retail pharmacies. The company operates in the generic pharma segment. It is a listed healthcare company in India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹30.60
+3.03% 1W | +122.40% 52W
Market Cap
1.6k CR
P/E Ratio
47
52W High
₹37.2
52W Low
₹10.4
Div. Yield
0%
Beta
–
50 DMA
₹20.4
200 DMA
₹15.2
Profit Margin
14%
Inst. Own.
0%
📊 CONSOLIDATION
📊 CONSOLIDATION
Fundamentals
Profit & Loss
| Metric | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 48.93 | 33.30 | 35.58 | 50.89 | 87.56 |
| Expenses | 31.74 | 27.06 | 23.30 | 35.60 | 71.97 |
| Operating Profit | 17.19 | 6.24 | 12.28 | 15.29 | 15.59 |
| OPM % | 35.13% | 18.74% | 34.51% | 30.05% | 17.80% |
| Other Income | 0.04 | 0.01 | 0.20 | 0.01 | 0.06 |
| Interest | 0.91 | 0.82 | 1.51 | 0.57 | 0.92 |
| Depreciation | 0.83 | 0.43 | 0.35 | 0.29 | 1.07 |
| Profit before tax | 15.49 | 5.00 | 10.62 | 14.44 | 13.66 |
| Tax % | -7.49% | 29.20% | 51.41% | 23.34% | 39.39% |
| Net Profit | 16.65 | 3.55 | 5.15 | 11.07 | 8.28 |
| EPS in Rs | 0.42 | 0.09 | 0.10 | 0.20 | 0.13 |
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Sales | 120 | 172 |
| Expenses | 88 | 124 |
| Operating Profit | 32 | 48 |
| OPM % | 27% | 28% |
| Other Income | 0 | 0 |
| Interest | 4 | 4 |
| Depreciation | 2 | 2 |
| Profit before tax | 27 | 43 |
| Tax % | 24% | 32% |
| Net Profit | 21 | 29 |
| EPS in Rs | 0.51 | 0.54 |
| Dividend Payout % | 0% | 0% |
Shareholding Pattern
Promoters52.68%
DIIs2.83%
Public44.49%
Promoters52.68%
FIIs0.23%
DIIs4.49%
Public42.60%
Promoters52.68%
FIIs0.32%
DIIs4.60%
Public42.40%
Promoters52.68%
FIIs1.67%
DIIs1.23%
Public44.43%
Promoters52.68%
FIIs0.32%
DIIs4.60%
Public42.40%
Promoters52.68%
FIIs1.67%
DIIs1.23%
Public44.43%
AHCL
Holdings Analysis
Key strengths & risk signals
77
Overall
69
Fundamental
85
Technical
Risks (1)
TOO MUCH PUBLIC HOLDING! 44.49% public ownership - higher volatility risk.
Strengths (4)
UNDERVALUED! PEG of 0.67 indicates stock is cheap relative to growth.
BULLISH TREND! 50-day average (20.4) is above 200-day average (15.2) - positive signal.
EXCELLENT YEAR! Stock gained 122.4% in the last year.
BULLISH SENTIMENT! In last 30 days: 19 up days, 11 down days. Avg volume on up days: 55,271,664 vs down days: 14,351,819. Ratio: 3.85x
Fundamental & Technical Analysis
77Overall
69Fundamental
85Technical
Fundamental Breakdown
Growth Quality
28/30
Revenue CAGR: 15.1% (VERY GOOD, 13/15). Profit CAGR: 69.8% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 14.0% profit margin - acceptable profitability.
PEG Valuation
10/10
UNDERVALUED! PEG of 0.67 indicates stock is cheap relative to growth.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 44.49% public ownership - higher volatility risk.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (20.4) is above 200-day average (15.2) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (30.6) is above both moving averages.
Trend Pattern
10/20
Current trend: CONSOLIDATION
52W Performance
10/10
EXCELLENT YEAR! Stock gained 122.4% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 19 up days, 11 down days. Avg volume on up days: 55,271,664 vs down days: 14,351,819. Ratio: 3.85x
RSI
3/5
BULLISH! RSI at 62.2 - positive momentum.
52W Range
4/5
UPPER HALF! Trading at 75.4% of 52W range - positive territory.
Momentum
5/5
STRONG MOMENTUM! Price has grown across all timeframes - up 3.0% (1 week), 56.2% (1 month), 101.6% (3 months). Momentum is accelerating.
Beta
3/5
MARKET ALIGNED! Beta of 1.00 - moves with the market.
AHCL
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-12 | Concall PDF | |
| Q4FY262026-06-09 | Concall PDF | |
| Q3FY262026-02-24 | Concall PDF | |
| Q2FY262025-11-24 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AHCL | ₹30.60 | 47 | 14.0% | 15.1% | 69.8% | +122.4% | 77 | CONSOLIDATION | +91.4% | -36.2% | +163.1% | +72.1% |
| FERMENTA | ₹521.00 | 25.2 | 11.7% | 14.5% | – | +13.9% | 66 | CONSOLIDATING UP | -55.5% | -49.5% | -10.6% | +0.2% |
| JAGSNPHARM | ₹222.50 | 33.2 | 15.5% | 6.7% | 17.3% | +6.5% | 70 | BREAKDOWN | +22.2% | +50.0% | +8.7% | +28.0% |
| AMRUTANJAN | ₹509.10 | 26.9 | 10.6% | 9.9% | 13.3% | -28.1% | 54 | HIT RESISTANCE | -47.0% | -72.8% | +9.6% | -31.2% |
| BETA | ₹1,677.70 | 23.4 | 11.1% | 19.2% | 10.5% | +13.7% | 66 | BREAKDOWN | +35.0% | +75.6% | +25.2% | +33.5% |
| HESTERBIO | ₹2,127.00 | 13.5 | 41.6% | 7.7% | 27.8% | +19.7% | 75 | BOUNCE FROM SUPPORT | +491.5% | +506.3% | -8.2% | -22.9% |
| WINDLAS | ₹935.20 | 29.9 | 7.1% | 20.7% | 16.0% | +3.6% | 74 | BREAKDOWN | 0.0% | +10.6% | +18.1% | +4.0% |
| SAKAR | ₹951.60 | 67.2 | 13.3% | 22.0% | 23.0% | +179.5% | 77 | BREAKDOWN | +112.8% | -9.1% | +38.5% | +2.7% |
Data from TradeAlone · Updated daily
